Tormentil for active ulcerative colitis: An open-label, dose-escalating study

Journal of Clinical Gastroenterology

Volumn 41, Issue 9, 2007, Pages 834-838

  Huber, Roman ^a   Ditfurth, Amelie V ^a   Amann, Frank ^b   Güthlin, Corina ^a   Rostock, Matthias ^a   Trittler, Rainer ^a   Kümmerer, Klaus ^a   Merfort, Irmgard ^b  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

Author keywords

CAI; Cohort study; Tannins; Ulcerative colitis

Indexed keywords

AMINOSALICYLIC ACID; ANTIOXIDANT; C REACTIVE PROTEIN; STEROID; TANNIN; TANNIN DERIVATIVE; TORMENTIL; UNCLASSIFIED DRUG;

ABDOMINAL CRAMP; ABDOMINAL DISCOMFORT; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; FEMALE; HEARTBURN; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; MEDICAL ASSESSMENT; NAUSEA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SAMPLE SIZE; SATIETY; SIDE EFFECT; THERAPY EFFECT; TREATMENT RESPONSE; ULCERATIVE COLITIS;

ADOLESCENT; ADULT; AGED; C-REACTIVE PROTEIN; CHROMATOGRAPHY, LIQUID; COLITIS, ULCERATIVE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MASS SPECTROMETRY; MIDDLE AGED; PHYTOTHERAPY; PLANT EXTRACTS; PLANTS, MEDICINAL; POTENTILLA; RHIZOME; SEVERITY OF ILLNESS INDEX; TANNINS;

EID: 34548851444     PISSN: 01920790     EISSN: None     Source Type: Journal    
DOI: 10.1097/MCG.0b013e31804b2173     Document Type: Article

References (28)

1. Hilsden RJ, Verhoef MJ, Best A, et al. Complementary and alternative medicine use by Canadian patients with inflammatory bowel disease: results from a national survey. Am J Gastroenterol. 2003;98:1563-1568.
2. Langhorst J, Anthonisen IB, Steder-Neukamm U, et al. Amount of systemic steroid medication is a strong predictor for the use of complementary and alternative medicine in patients with inflammatory bowel disease: results from a German national survey. Inflamm Bowel Dis. 2005;11:287-295.
3. Moody GA, Eaden JA, Bhakta P, et al. The role of complementary medicine in European and Asian patients with inflammatory bowel disease. Public Health. 1998;112:269-271.
4. Subbotina MD, Timchenko VN, Vorobyov MM, et al. Effect of oral administration of tormentil root extract (potentilla tormentilla) on rotavirus diarrhea in children: a randomised, double blind, controlled trial. Pediatr Infect Dis J. 2003;22:706-710.
5. Raedsch R, Walter-Sack I, Galle PR, et al. Prophylaxis of traveler's diarrhea in Egypt: results of a double blind controlled study. Klin Wochenschr. 1991;69:863-866.
6. Langmead L, Dawson C, Hawkins C, et al. Antioxidant effects of herbal therapies used by patients with inflammatory bowel disease: an in vitro study. Aliment Pharmacol Ther. 2002;16:197-205.
7. Rachmilewitz D. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. Br Med J. 1989;298:82-86.
8. Sticher O. Gerbstoffe. In: Hänsel R, ed. Pharmakognosie- Phytopharmazie. Berlin, Heidelberg, Germany: Springer; 1999:870-890.
9. Hager H. Tormentillae rhizoma. In: Hager H, ed. Handbuch der Pharmazeutischen Praxis. Heidelberg, Germany: Springer; 2002: 254-269.
10. Kruis W, Bar-Meir S, Feher J, et al. The optimal dose of 5-aminosalicylic acid in ulcerative colitis: a dose finding study with newly developed mesalamine. Clin Gastroenterol Hepatol. 2003;1:36-43.
11. Ehrlich M, Trittler R, Daschner FD, et al. A new and rapid method for drug monitoring the new oxazolidinone antibiotic linezolid in serum and urine by HPLC-integrated sample preparation. J Chromatogr B. 2001;755:373-375.
12. Egle H, Trittler R, Kümmerer K. An advanced double column-switching technique with LC-LC for liquid chromatography/electrospray ionisation mass spectrometry for fully automated analysis of caspofungin. Rapid Commun Mass Spectrom. 2004;18:2871-2877.
13. Cohen J. Statistical Power Analysis for the Behavioural Sciences. Hillsdale: Lawrence Erlbaum; 1987.
14. Hilsden RJ, Verhoef MJ. Complementary and alternative medicine: evaluating its effectiveness in inflammatory bowel disease. Inflamm Bowel Dis. 1998;4:318-323.
15. Joos S, Rosemann T, Szecsenyi J, et al. Use of complementary and alternative medicine in Germany-a survey of patients with inflammatory bowel disease. BMC Complement Altern Med. 2006;22:19.
16. Kong SC, Hurlstone DP, Pocock CY, et al. The incidence of self-prescribed oral complementary and alternative medicine use by patients with gastrointestinal diseases. J Clin Gastroenterol. 2005;39:138-141.
17. Manach C, Williamson G, Morand C, et al. Bioavailability and bioefficacy of polyphenols in humans I. Review of 97 bioavailability studies. Am J Clin Nutr. 2005;81(suppl):230-242.
18. Williamson G, Manach C. Bioavailability and bioefficacy of polyphenols in humans II. Review of 93 intervention studies. Am J Clin Nutr. 2005;81(suppl):243-255.
19. Probert CS, Hearing SD, Schreiber S, et al. Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial. Gut. 2003;52:998-1002.
20. Rizzello F, Gionchetti P, D'Arienzo A, et al. Oral beclometasone dipropionate in the treatment of active ulcerative colitis. A double-blind, placebo-controlled study. Aliment Pharmacol Ther. 2002;16:1109-1116.
21. Pokrotnieks J, Marlicz K, Paradowski L, et al. Efficacy and tolerability of mesalazine foam enema (Salofalk foam) for distal ulcerative colitis: a double-blind, randomized, placebo-controlled study. Aliment Pharmacol Ther. 2000;14:1191-1198.
22. Hrobjartsson A, Gotzsche PC. Is the placebo powerless? An analysis of clinical trials comparing placebo with no treatment. N Engl J Med. 2001;344:1594-1602.
23. Hrobjartsson A, Gotzsche PC. Is the placebo powerless? Update of a systemic review with 52 new randomised trials comparing placebo with no treatment. J Intern Med. 2004;256:91-100.
24. Vennat B, Bos MA, Pourrat A, et al. Procyanidins from tormentil: fractionation and study of the anti-radical activity towards superperoxide anion. Biol Pharm Bull. 1994;17:1613-1615.
25. Rimpler H. Komplexe Gerbstoffe. In: Rimpler H, ed. Biogene Arzneistoffe. Stuttgart, Germany: Deutscher Apotheker Verlag; 1999:394-397.
26. Horz KH, Reichling J. Tormentilla. In: Hager H, ed. Hager ROM. Heidelberg, Germany: Springer; 2004.
27. Wichtl M. Tormentillae rhizoma. In: Wichtl M, ed. Teedrogen und Phytopharmaka. Ein Handbuch für die Praxis auf Wissenschafticher Grundlage. Stuttgart, Germany: Wissenschaftliche Verlagsgesellschaft Stuttgart; 2002:614-616.
28. Linskens RK, Huijsdens XW, Savelkoul PH, et al. The bacterial flora in inflammatory bowel disease: current insights in pathogenesis and the influence of antibiotics and probiotics. Scand J Gastroenterol. 2001;234(suppl):29-40.